Newest figures come from the filing for FY2025, filed Feb 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CURLD SEC filings page.
Curaleaf Holdings Inc New (CURLD) reported $1.3B in revenue for fiscal year 2025, down 5.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for Curaleaf Holdings Inc New, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Curaleaf Holdings Inc New passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Curaleaf Holdings Inc New reported a net loss of $231.1M while generating $137.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Curaleaf Holdings Inc New earns $0.48 in operating income for every $1 of interest expense ($25.4M vs $53.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Curaleaf Holdings Inc New generated $1.3B in revenue in fiscal year 2025. This represents a decrease of 5.0% from the prior year.
Curaleaf Holdings Inc New's EBITDA was $222.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.3% from the prior year.
Curaleaf Holdings Inc New reported a net loss of $231.1M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Curaleaf Holdings Inc New earned -$0.35 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
Curaleaf Holdings Inc New generated $74.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 4.3% from the prior year.
Curaleaf Holdings Inc New held $101.6M in cash against $512.9M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Curaleaf Holdings Inc New's gross margin was 49.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.7 percentage points from the prior year.
Curaleaf Holdings Inc New's operating margin was 2.0% in fiscal year 2025, reflecting core business profitability. This is up 0.2 percentage points from the prior year.
Curaleaf Holdings Inc New's net profit margin was -18.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 2.1 percentage points from the prior year.
Curaleaf Holdings Inc New's ROE was -30.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 5.5 percentage points from the prior year.
Capital Allocation
Curaleaf Holdings Inc New invested $805K in research and development in fiscal year 2025. This represents a decrease of 43.3% from the prior year.
Curaleaf Holdings Inc New invested $63.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 31.4% from the prior year.
Not reported for fiscal year 2025.
CURLD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing |
|---|---|---|---|---|---|
| Revenue | $1.3B-5.0% | $1.3B-0.9% | $1.3B+5.6% | $1.3B+6.6% | $1.2B |
| Cost of Revenue | $637.1M-8.1% | $693.5M-5.3% | $732.2M+12.8% | $649.0M+3.6% | $626.2M |
| Gross Profit | $631.0M-1.5% | $640.8M+4.3% | $614.4M-1.9% | $626.4M+9.9% | $569.8M |
| R&D Expenses | $805K-43.3% | $1.4M | N/A | N/A | N/A |
| SG&A Expenses | $428.4M+2.4% | $418.5M+0.9% | $414.8M-1.2% | $419.9M+8.6% | $386.6M |
| Operating Income | $25.4M+2.9% | $24.7M-42.3% | $42.9M-34.0% | $65.0M+11.0% | $58.6M |
| EBITDA | $222.1M-13.3% | $256.2M+7.3% | $238.8M+8.1% | $221.0M+23.4% | $179.1M |
| Interest Expense | $53.5M+0.6% | $53.2M-1.0% | $53.7M | N/A | N/A |
| Income Tax | $123.7M+25.9% | $98.3M-14.3% | $114.6M-35.9% | $178.8M+17.3% | $152.4M |
| Net Income | -$231.1Mn/m | -$215.4Mn/m | -$281.2Mn/m | -$370.1Mn/m | -$205.9M |
| EPS (Basic) | -$0.35n/m | -$0.32n/m | -$0.39n/m | -$0.52n/m | -$0.29 |
| EPS (Diluted) | -$0.35n/m | -$0.32n/m | -$0.39n/m | -$0.52n/m | -$0.29 |
| Diluted Shares (Avg) | 762M+2.9% | 741M+2.3% | 724M+1.8% | 711M+1.8% | 699M |
CURLD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing |
|---|---|---|---|---|---|
| Total Assets | $2.8B-3.5% | $2.9B-4.7% | $3.1B-9.3% | $3.4B+10.0% | $3.1B |
| Current Assets | $448.6M+3.3% | $434.4M+3.8% | $418.6M-35.8% | $652.4M-10.2% | $726.6M |
| Cash & Equivalents | $101.6M-5.3% | $107.2M+16.8% | $91.8M-43.7% | $163.2M-45.5% | $299.3M |
| Inventory | $225.0M+3.7% | $216.9M+0.5% | $215.9M-8.0% | $234.8M-5.4% | $248.1M |
| Accounts Receivable | $73.9M+15.4% | $64.0M+6.7% | $60.0M+32.8% | $45.2M-25.2% | $60.4M |
| Goodwill | $635.1M+1.0% | $628.9M+0.4% | $626.6M+0.2% | $625.1M+9.4% | $571.7M |
| Total Liabilities | $2.0B+2.5% | $2.0B+1.6% | $1.9B-4.4% | $2.0B+39.8% | $1.4B |
| Current Liabilities | $294.3M-24.1% | $387.9M-21.5% | $494.0M-0.6% | $496.9M+57.1% | $316.2M |
| Non-Current Liabilities | $1.7B+9.1% | $1.6B+9.6% | $1.4B-5.6% | $1.5B+35.0% | $1.1B |
| Long-Term Debt | $512.9M+9.9% | $466.9M-14.8% | $548.3M-3.9% | $570.8M+24.6% | $457.9M |
| Total Equity | $756.4M-12.2% | $861.2M-18.0% | $1.1B-17.9% | $1.3B-17.2% | $1.5B |
| Retained Earnings | -$1.6Bn/m | -$1.4Bn/m | -$1.1Bn/m | -$859.6Mn/m | -$489.5M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
CURLD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing |
|---|---|---|---|---|---|
| Operating Cash Flow | $137.7M-15.8% | $163.6M+117.4% | $75.3M+62.2% | $46.4Mn/m | -$58.3M |
| Depreciation & Amortization | $196.6M-15.1% | $231.5M+18.2% | $195.9M+25.6% | $156.0M+29.4% | $120.5M |
| Stock-Based Compensation | $35.7M+39.1% | $25.7M+28.4% | $20.0M-28.6% | $28.0M-29.0% | $39.5M |
| Capital Expenditures | $63.4M-31.4% | $92.4M+41.2% | $65.4M-51.4% | $134.6M-21.7% | $172.0M |
| Free Cash Flow | $74.3M+4.3% | $71.2M+625.3% | $9.8Mn/m | -$88.2Mn/m | -$230.2M |
| Investing Cash Flow | -$70.3Mn/m | -$93.8Mn/m | -$78.7Mn/m | -$219.9Mn/m | -$164.0M |
| Financing Cash Flow | -$73.5Mn/m | -$54.2Mn/m | -$67.0M-260.4% | $41.8M-90.7% | $449.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CURLD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing |
|---|---|---|---|---|---|
| Gross Margin | 49.8%+1.7pp | 48.0%+2.4pp | 45.6%-3.5pp | 49.1%+1.5pp | 47.6% |
| Operating Margin | 2.0%+0.2pp | 1.8%-1.3pp | 3.2%-1.9pp | 5.1%+0.2pp | 4.9% |
| Net Margin | -18.2%-2.1pp | -16.2%+4.7pp | -20.9%+8.1pp | -29.0%-11.8pp | -17.2% |
| Return on Equity | -30.6%-5.5pp | -25.0%+1.8pp | -26.8%+2.2pp | -28.9%-15.6pp | -13.3% |
| Return on Assets | -8.1%-0.8pp | -7.3%+1.8pp | -9.1%+1.8pp | -10.8%-4.2pp | -6.6% |
| Current Ratio | 1.52+0.4x | 1.12+0.3x | 0.85-0.5x | 1.31-1.0x | 2.30 |
| Debt-to-Equity | 0.68+0.1x | 0.540.0x | 0.52+0.1x | 0.45+0.1x | 0.30 |
| Liabilities-to-Equity | 2.65+0.4x | 2.27+0.4x | 1.83+0.3x | 1.57+0.6x | 0.93 |
| Asset Turnover | 0.450.0x | 0.450.0x | 0.43+0.1x | 0.370.0x | 0.39 |
| FCF Margin | 5.9%+0.5pp | 5.3%+4.6pp | 0.7%+7.6pp | -6.9%+12.3pp | -19.3% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Curaleaf Holdings Inc New CURLD | FY2025 | $1.3B | -$231.1M | -18.2% | N/A | — |
| Takeda Pharm Co Ltd TKPHF | FY2026 | $28.3B | -$957.9M | -3.4% | $68.8B | — |
| Haleon plc GBP1.25 HLNCF | FY2025 | $14.8B | $2.2B | 15.1% | $39.6B | — |
Where Curaleaf Holdings Inc New Ranks
Frequently Asked Questions
Curaleaf Holdings Inc New (CURLD) reported $1.3B in total revenue for fiscal year 2025. This represents a -5.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Curaleaf Holdings Inc New (CURLD) revenue declined by 5.0% year-over-year, from $1.3B to $1.3B in fiscal year 2025.
No, Curaleaf Holdings Inc New (CURLD) reported a net loss of $231.1M in fiscal year 2025, with a net profit margin of -18.2%.
Curaleaf Holdings Inc New (CURLD) had EBITDA of $222.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Curaleaf Holdings Inc New (CURLD) had $101.6M in cash and equivalents against $512.9M in long-term debt.
Curaleaf Holdings Inc New (CURLD) had a gross margin of 49.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Curaleaf Holdings Inc New (CURLD) had an operating margin of 2.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Curaleaf Holdings Inc New (CURLD) had a net profit margin of -18.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Curaleaf Holdings Inc New (CURLD) has a return on equity of -30.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Curaleaf Holdings Inc New (CURLD) generated $74.3M in free cash flow during fiscal year 2025. This represents a 4.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Curaleaf Holdings Inc New (CURLD) generated $137.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Curaleaf Holdings Inc New (CURLD) had $2.8B in total assets as of fiscal year 2025, including both current and long-term assets.
Curaleaf Holdings Inc New (CURLD) invested $63.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Curaleaf Holdings Inc New (CURLD) invested $805K in research and development during fiscal year 2025.
Curaleaf Holdings Inc New (CURLD) had a current ratio of 1.52 as of fiscal year 2025, which is generally considered healthy.
Curaleaf Holdings Inc New (CURLD) had a debt-to-equity ratio of 0.68 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Curaleaf Holdings Inc New (CURLD) had a liabilities-to-equity ratio of 2.65 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Curaleaf Holdings Inc New (CURLD) had a return on assets of -8.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Curaleaf Holdings Inc New (CURLD) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Curaleaf Holdings Inc New (CURLD) reported a net loss of $231.1M while generating $137.7M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Curaleaf Holdings Inc New (CURLD) has an interest coverage ratio of 0.48x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.